Clonal hematopoiesis, a hidden buildup of mutated blood stem cells, raises heart disease risk independent of cholesterol and blood pressure. Inside the science of CHIP and the new field of…
Five-year data from the KEYNOTE-942 trial, presented at ASCO 2026, show that intismeran autogene plus Keytruda sustains a 49% reduction in melanoma recurrence risk and drives overall survival to 92.2%…
A landmark phase 3 trial of 4,429 patients showed the Prosigna 50-gene genomic test can safely spare two-thirds of clinically high-risk breast cancer patients from chemotherapy, with equivalent five-year survival…
A bispecific antibody that simultaneously targets PD-1 and VEGF just beat the standard immunotherapy regimen head-to-head in overall survival. It is the first time any drug has achieved this milestone…
A landmark Nature study from Mass General Brigham led by Alexander Tyshkovskiy and Vadim Gladyshev identifies gene expression signatures so fundamental to biological aging that they appear nearly identically across…
A Phase 3 trial just cut the risk of death by 60 percent in metastatic pancreatic cancer, a disease that has resisted nearly every therapeutic advance for four decades. The…
At ASCO 2026, izalontamab brengitecan became the first bispecific antibody-drug conjugate to improve both progression-free and overall survival in triple-negative breast cancer. Inside the EGFRxHER3 mechanism, the Phase 3 trial…
A new class of AI foundation models trained on millions of whole slide images is reshaping how cancer is diagnosed. Inside Virchow 2, Prov-GigaPath, CHIEF, and the FDA clearance of…
More than thirty targeted protein degraders are now in human trials, with the first Phase 3 readouts arriving in 2026. Inside the vepdegestrant breast cancer data, the BTK degrader race,…
A landmark Science study from Israel’s Weizmann Institute reveals that genetics accounts for roughly 50% of variation in human lifespan, more than double previous estimates, upending decades of thinking about…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.